Jakub Hlavka
Personal Details
First Name: | Jakub |
Middle Name: | |
Last Name: | Hlavka |
Suffix: | |
RePEc Short-ID: | phl25 |
[This author has chosen not to make the email address public] | |
https://sites.google.com/view/jakubhlavka/ | |
Affiliation
(1%) Leonard D. Schaeffer Center for Health Policy and Economics
University of Southern California
Los Angeles, California (United States)http://healthpolicy.usc.edu/
RePEc:edi:chuscus (more details at EDIRC)
(99%) Ekonomicko-správní fakulta
Masarykova Univerzita
Brno, Czech Republichttp://www.econ.muni.cz/
RePEc:edi:emunicz (more details at EDIRC)
Research output
Jump to: Working papers ArticlesWorking papers
- Marlon Graf & Jakub P. Hlavka & Bonnie L. Triezenberg, 2016. "A Change is in the Air Emerging Challenges for the Cloud Computing Industry," Working Papers WR-1144, RAND Corporation.
Articles
- Jakub P. Hlávka & Tara A. Lavelle & Peter J. Neumann & Pei-Jung Lin, 2022. "Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers," PharmacoEconomics, Springer, vol. 40(7), pages 647-652, July.
- Jakub P. Hlávka & Jeffrey C. Yu & Dana P. Goldman & Darius N. Lakdawalla, 2021. "The economics of alternative payment models for pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 559-569, June.
- Jakub P. Hlávka & Soeren Mattke & Asa Wilks, 2020. "The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis," Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 669-677, October.
- Jakub P Hlávka, 2017. "Portfolio Society: On the Capitalist Mode of Prediction," Science and Public Policy, Oxford University Press, vol. 44(6), pages 879-880.
Citations
Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.Blog mentions
As found by EconAcademics.org, the blog aggregator for Economics research:- Jakub P. Hlávka & Soeren Mattke & Asa Wilks, 2020.
"The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis,"
Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 669-677, October.
Mentioned in:
- Chris Sampson’s journal round-up for 19th October 2020
by Chris Sampson in The Academic Health Economists' Blog on 2020-10-19 11:00:05
- Chris Sampson’s journal round-up for 19th October 2020
Working papers
-
Sorry, no citations of working papers recorded.
Articles
- Jakub P. Hlávka & Jeffrey C. Yu & Dana P. Goldman & Darius N. Lakdawalla, 2021.
"The economics of alternative payment models for pharmaceuticals,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 559-569, June.
Cited by:
- Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
- Levaggi, Laura & Levaggi, Rosella, 2024. "Competition, value-based prices and incentives to research personalised drugs," Socio-Economic Planning Sciences, Elsevier, vol. 93(C).
- Jakub P. Hlávka & Soeren Mattke & Asa Wilks, 2020.
"The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis,"
Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 669-677, October.
Cited by:
- Dubois, Pierre & Magnac, Thierry, 2024.
"Optimal intertemporal curative drug expenses: The case of hepatitis C in France,"
Journal of Health Economics, Elsevier, vol. 94(C).
- Pierre Dubois & Thierry Magnac, 2024. "Optimal Intertemporal Curative Drug Expenses: The Case of Hepatitis C in France," Post-Print hal-04501256, HAL.
- Magnac, Thierry & Dubois, Pierre, 2023. "Optimal Intertemporal Curative Drug Expenses: The Case of Hepatitis C in France," TSE Working Papers 23-1402, Toulouse School of Economics (TSE).
- Dubois, Pierre & Magnac, Thierry, 2024.
"Optimal intertemporal curative drug expenses: The case of hepatitis C in France,"
Journal of Health Economics, Elsevier, vol. 94(C).
More information
Research fields, statistics, top rankings, if available.Statistics
Access and download statistics for all items
NEP Fields
NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 1 paper announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.- NEP-PAY: Payment Systems and Financial Technology (1) 2018-03-12. Author is listed
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.
To update listings or check citations waiting for approval, Jakub Hlavka should log into the RePEc Author Service.
To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.
To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.
Please note that most corrections can take a couple of weeks to filter through the various RePEc services.